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Abstract
We generated a panel of eight rat IgG2a monoclonal
antibodies with high affinity for mouse VEGFR2 (KDR/
Flk-1), the main receptor that mediates the angiogenic
effect of VEGF-A. The antibodies (termed RAFL, Rat
Anti Flk ) bound to dividing endothelial cells more
strongly than they did to nondividing cells. Most of the
RAFL antibodies blocked [125I]VEGF165 binding to
VEGFR2. Three of eight antibodies localized to
VEGFR2-positive tumor endothelium after intravenous
injection into mice bearing orthotopic MDA-MB-231
breast carcinomas, as judged by indirect immunohis-
tochemistry. An average of 60% of vessels in the
tumors was stained. The majority (50–80%) of vessels
were also stained in a variety of other human and
murine tumors growing in mice. The antibodies did not
bind detectably to the vascular endothelium in normal
heart, lung, liver, and brain cortex, whereas the
vascular endothelium in kidney glomerulus and pan-
creatic islets was stained. Treatment of mice bearing
orthotopic MDA-MB-231 tumors with RAFL-1 antibody
inhibited tumor growth by an average of 48% and
reduced vascular density by 65%, compared to tumors
in mice treated with control IgG. Vascular damage was
not observed in normal organs, including kidneys and
pancreas. These studies demonstrate that anti-
VEGFR2 antibodies have potential for vascular target-
ing and imaging of tumors in vivo.
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Introduction
Angiogenesis, the growth of new blood vessels from exist-
ing vessels [1], is of crucial importance for the growth,
maintenance, and metastasis of solid tumors [2,3]. Vascular
endothelial growth factor (VEGF-A) is one of the key
angiogenic factors that stimulates vascularization of normal
and neoplastic tissues. Evidence for the dominant role of
VEGF in the development of tumor angiogenesis includes
its high expression in a broad spectrum of malignancies
[4,5]; induction of mitogenic, chemotactic, and antiapoptotic
effects on cultured endothelial cells [6–8]; induction of vascular
leakage [5,9]; and the ability to stimulate the full cascade of
events required for angiogenesis in vivo [10,11].
VEGF-A exerts its effects on the vascular endothelium
through binding to two high-affinity receptors, R1 (FLT-1/Flt-1)
and R2 (KDR and Flk-1 for the human and mouse receptors,
respectively). Several lines of evidence indicate that VEGFR2
plays the major role in transducing the angiogenic effect of
VEGF on tumor vasculature. The expression of VEGFR2 is
mainly restricted to vascular endothelial cells and hematopoietic
cells [12,13]. Upon addition of VEGF to mouse or human
endothelial cells that have both receptors, tyrosine phospho-
rylation is primarily detected in VEGFR2 [14]. Neither phospho-
rylation nor mitotic, migratory, and morphological changes
associated with VEGF are apparent in endothelial cells that
have been engineered to express VEGFR1 alone [14,15].
Hypoxia and genetic alterations in tumor cells continuously drive
overexpression of both receptors on tumor vessels in vivo, with
VEGFR2 being consistently found at higher levels than
VEGFR1 [16]. Studies in our laboratory showed that the anti-
VEGF antibody, 2C3, which blocks VEGF binding to VEGFR2
but not to VEGFR1, inhibits tumor growth and angiogenesis as
efficiently as does 4.6.1 antibody [17], which neutralizes the
binding of VEGF to both receptors [18]. Taken together, these
observations indicate that VEGFR2 is able tomediate all known
functions of VEGF on vascular endothelial cells whereas
VEGFR1 might play a minor or indirect role [19,20].
The specificity of VEGFR2 expression, its location on the
surface of the tumor vessels, and its predominant role in
tumor angiogenesis make it a highly desirable target for
the development of both antiangiogenic and vascular
targeting drugs. Mouse tumor models represent a major
testing system to evaluate such drugs. Surprisingly, only one
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monoclonal antibody (DC101) with definite specificity for
mouse VEGFR2 (Flk-1) has been described [21]. DC101
has been shown to inhibit the phosphorylation of Flk-1,
VEGF-dependent DNA synthesis in cultured cells, neoangio-
genesis in Matrigel plugs and tumors in vivo, and tumor
growth in animal models [21]. To our knowledge, immuno-
histochemical detection of native VEGFR2 by monoclonal
antibodies has not been documented in the literature,
although several polyclonal anti-VEGFR2 antibodies, includ-
ing the TO14 antibody produced in our laboratory [22,23],
have been successfully used for this purpose.
In the present study, we raised monoclonal anti-VEGFR2
antibodies that recognize native VEGFR2. The monoclonal
antibodies have high affinity for Flk-1 in enzyme-linked
immunosorbent assay (ELISA), recognize Flk-1 on frozen
tissue sections and on cultured mouse endothelial cells,
compete with [125I]VEGF165 for binding in vitro, and localize
specifically to Flk-1–positive tumor vessels in vivo. These
antibodies are useful reagents for monitoring the expression
of the VEGFR2 protein in mouse tumor models and for
exploring the vascular targeting and imaging potential of this
tumor endothelial marker.
Materials and Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), gluta-
mine, sodium pyruvate, and nonessential amino acids were
obtained from Life Technologies (Grand Island, NY). Human
recombinant [125I]VEGF165 with a specific activity of 2000
ACi/ng was purchased from Perkin Elmer (Boston, MA).
Purified mouse Flt-1 and Flt-4 proteins were purchased from
R&D Systems (Minneapolis, MN).
Antibodies
Rat antimouse CD31 antibody was from PharMingen
(San Diego, CA). Antimouse Flt-1 antibody (clone 10.2)
was from Biodesign International (Saco, ME). Noncompeting
mouse monoclonal (clone 1A8) and rabbit polyclonal anti-
bodies (TO14) against murine Flk-1 were produced in our
laboratory and previously described [22,23]. Goat antirat,
antimouse, and antirabbit secondary antibodies conjugated
to horseradish peroxidase (HRP) were purchased from Dako
(Carpinteria, CA).
Cell Culture
Murine brain endothelioma bEnd.3 cells were provided by
Prof. Werner Risau (Max Plank Institution, Munich, Ger-
many). L540Cy human Hodgkin’s lymphoma cells were
provided by Prof. V. Diehl (Ko¨ln, Germany). NCI-H358
human nonsmall cell lung carcinoma was provided by
Dr. Adi Gazdar (Southwestern Medical Center, Dallas, TX).
Meth A mouse fibrosarcoma, 3LL mouse lung carcinoma,
and MDA-MB-231 human breast carcinoma were obtained
from American Type Cell Collection (Rockville, MD). Tumor
and endothelial cells were maintained in DMEM supple-
mented with 10% fetal calf serum, 2 mM L-glutamine,
2 U/ml penicillin G, and 2 Ag/ml streptomycin, and subcul-
tured using 0.125% trypsin in phosphate-buffered saline
(PBS) solution containing 0.2% EDTA. L540Cy cells were
maintained in RPMI medium with the same supplements.
Tumor cells intended for injection into mice were washed
once and resuspended in serum-free medium. Cell number
and viability were determined by staining with 0.2% trypan
blue dye. Only single-cell suspensions of greater than 90%
viability were used for in vivo studies.
Generation of Rat Monoclonal Antibodies Against Mouse
VEGFR2 (Flk-1)
The soluble domain of mouse VEGFR2 was expressed in
Sf9 insect cells and purified to homogeneity as previously
described [22]. Normal, 6-week-old, female Lewis rats were
purchased from Charles River (Wilmington, MA) and used
for immunizations. Purified Flk-1 (100 Ag per injection) was
mixed with Titer-Max (Corixa, Seattle, WA) and injected at
four subcutaneous sites. The injections were repeated four
more times. Titer of polyclonal antibodies was determined
2 days after each immunization. When the titer reached
1,000,000, rats were sacrificed and their spleens were
harvested for fusion with myeloma partner P3X63AG8.653
line (653 cells), obtained from ATCC. Alternatively, spleno-
cytes from immunized rats were fused with 653 cells stably
transfected with the apoptotic inhibitor, CrmA [24]. Prior
studies determined that 653CrmA fusants display improved
survival and clonogenicity during the isolation and expansion
of single hybridoma clones. Positive wells were identified by
screening on immobilized Flk-1 and were subcloned three
times using limiting dilution. The rat immunoglobulin isotype
was determined using a kit from Zymed Laboratories (San
Francisco, CA). This panel of monoclonal antibodies was
termed RAFLs (Rat Anti Flk). Individual antibodies from this
panel were identified by sequential numbers (RAFL-1,
RAFL-2, etc.).
Antibody Purification
Antibodies were purified from supernatants of hybrid-
oma lines grown in Integra flasks (Integra Biosciences,
East Dundee, IL). Supernatants were centrifuged, filtered
through 0.22-Am filters, and loaded onto Sepharose-
Protein G columns. IgG was eluted with citric acid buffer
(pH 3.5), dialyzed into PBS, and stored thereafter at 4jC in
the same buffer. Purity was estimated by SDS-PAGE and
was routinely >95%.
Binding to Plastic Immobilized Soluble Domain of Mouse
VEGFR2 on ELISA
All steps of the ELISA procedure were performed at room
temperature. Microtiter plates were coated with the soluble
domain of Flk-1 (1 Ag/ml). Tissue culture supernatants from
hybridoma lines or purified IgG were added to the wells in the
presence of 2% BSA diluted in PBS. After 2 hours, plates
were washed and incubated for 1 hour with goat antirat
IgG (Fc gamma–specific) conjugated to HRP. Peroxidase
activity was measured by adding O-phenylenediamine
(0.5 mg/ml) and hydrogen peroxidase (0.03% wt/vol) in
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citrate–phosphate buffer (pH 5.5). The reaction was stopped
by 100 Al of 0.18 M H2SO4. The absorbance was read at
490 nm. Experiments were performed in triplicate and were
repeated three times.
Recognition of Mouse VEGFR2 on the Surface of Intact
Mouse Endothelial Cells bEnd.3
bEnd.3 cells were seeded at a density of 50,000 cells/ml
(0.5 ml per well) on sterile Lab-Tek II chamber glass slides
(Nalge Nunc International, Naperville, IL) 2 days before the
assay. Cells were washed twice with DPBS containing 2 mM
Ca2+ and Mg2+ and 0.2% (wt/vol) gelatin as a carrier protein.
In some experiments, cells were fixed with 0.25% glutaral-
dehyde prior to incubation with antibodies. Antibodies were
added at the concentration of 2 Ag/ml and incubated with
cells for 2 hours at RT. The monolayer was subsequently
washed and incubated with goat antirat IgG–HRP conjugate
(1:500 dilution). VEGFR2-positive cells were detected by the
addition of carbazole substrate, generating insoluble red
brownish precipitate. The substrate was removed after
15 minutes of incubation and cells were counterstained using
Mayer’s hematoxylin solution (Sigma, St. Louis, MO). The
control rat IgG and secondary antibody alone did not stain.
Each experiment was repeated at least twice.
Competition of Anti-VEGFR2 Antibodies with [125I]VEGF165
for the Binding to VEGFR2 on Cell Surfaces
Binding assays were performed using mouse bEnd.3
endothelial cells. Cells were seeded in 48-well plates at a
density of 50,000 cells/ml 48 hours before the assay. Cells
were washed with DPBS containing 2 mM Ca2+ and Mg2+
and 0.2% (wt/vol) gelatin as a carrier protein (binding buffer).
Human recombinant [125I]VEGF165 was diluted in the binding
buffer to a final concentration of 25 pM. This concentration
gives 90% of saturation binding on bEnd.3 cells. RAFL anti-
bodies were immediately added at various concentrations
(0.5–10 Ag/ml). Rat IgG2a of irrelevant specificity was used
as a negative control. Cells were incubated with the mixture
of [125I]VEGF165 and anti–Flk-1 antibodies for 4 hours at
4jC. Monolayers were washed three times with the binding
buffer and dissolved by the addition of 0.5 M NaOH. Radio-
activity was quantified using a gamma counter. Nonspecific
binding was determined in the presence of a 100-fold molar
excess of cold VEGF and was found to be 8% to 10% of total.
The value of specific VEGF binding in the presence of control
rat IgG2a (5 Ag/ml) was taken as 100%. Percent of blocking
was calculated according to the following formula:
Total net cpm Net cpm in the presence of competitor
Total cpm
 100
Each experiment was performed in duplicate and repeated
three times.
Immunohistochemical Detection of Mouse VEGFR2 on
Frozen Sections
Frozen sections of mouse normal organs and human
tumors grown in nude mice were fixed with acetone for
5 minutes and rehydrated with PBST for 10 minutes. Sec-
tions were overlaid with undiluted hybridoma supernatants or
Figure 1. Binding of RAFL antibodies to mouse VEGFR2 in ELISA. The extracellular domain of mouse VEGFR2 was immobilized on plastic by incubating 96-well
plates with 1 lg/ml purified protein. RAFL antibodies were added at concentrations ranging from 6.7 to 0.005 nM. The bound antibodies were detected with goat
antirat IgG conjugated to peroxidase. Results show absorbance at 490 nm that reflects peroxidase activity. Each point is the average of triplicate measurements,
the standard deviations of which did not exceed 5% of the mean value.
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purified antibodies solutions (10 Ag/ml). All dilutions were
prepared in PBST containing 0.2% BSA. Affinity-purified
rabbit anti –Flk-1 antibody TO14, which was previously
raised in our laboratory [23], was used as a positive control
for immunohistochemical studies. Rat anti-CD31 antibody
was used to identify endothelial cells on sections. Secondary
antibodies were either antirat or rabbit IgG, conjugated to
peroxidase. HRP activity was detected by developing with
either carbazole or DAB substrates.
Growth of Tumors for Localization Studies
For localization studies, 2107 L540 human Hodgkin’s
lymphoma cells or 1107 cells of other tumor types lines
were injected subcutaneously into the right flank of SCID
mice (Charles River). MDA-MB-231 cells were injected into
the mammary fat pad (MFP) of female nude mice (orthotopic
model). Tumors were allowed to reach a volume of 0.4 to
0.7 cm3. A minimum of three animals per tumor group
was used.
Table 1. Functional Properties of Rat Monoclonal Antibodies Against VEGFR2.
Antibody ELISA (pM)* VEGF Blocking (%)y Binding to Cell Surfacez Binding to Localization to
Unfixed Fixed
Frozen Sections§ Vessels In Vivob
RAFL-1 15 34 Yes No 4+ Yes
RAFL-2 23 55 Yes Yes 4+ Yes
RAFL-3 67 48 Yes Yes 2+ Yes
RAFL-4 10 12 No No – No
RAFL-5 50 51 Yes No 2+ No
RAFL-6 27 16 No Yes 2+ No
RAFL-7 30 49 Yes Yes 2+ No
RAFL-8 70 42 Yes No 1+ No
TO14 25 32 Yes Yes 4+ Yes
Control rat IgG N/A 10 No No – No
*Concentration of antibody required to achieve half-maximal binding to immobilized VEGFR2 in ELISA.
yMaximal percent of [125I]VEGF165 displacement by 2 Ag/ml antibody added to competitive assay.
zDetermined by staining of either 0.25% glutaraldehyde fixed or native bEnd.3 cells using 2 Ag/ml primary antibody.
§Determined by staining frozen sections of tumors and kidney using 10 Ag/ml antibody. Intensity of staining was scored by comparing to that produced by a pan-
endothelial marker MECA 32: ( – ) no staining; (1+) weak; (2+) moderate; (3+) moderate to strong; (4+) strong, MECA 32– like intensity.
b
Determined by specific detection of rat IgG on vasculature of tumors and kidney derived from nude mice bearing orthotopic MDA-MB-231 human breast tumors.
Figure 2. Binding of RAFL-1 and RAFL-6 antibodies to mouse endothelial cells. Cultures of bEnd.3 endothelial cells, which contained both dividing and nondividing
cells, were grown on sterile glass slides. Binding of RAFL antibodies to unfixed cells (A) or fixed cells (B) was examined. Arrows point to strongly stained endothelial
cells that display morphological characteristics typical of cells during metaphase (A) or telophase (A,B). Arrowheads point to neighboring cells lacking
morphological signs of cell division that were not stained by either RAFL-1 or RAFL-6.
300 Monoclonal Antibodies Against Mouse VEGFR2 Ran et al.
Neoplasia . Vol. 5, No. 4, 2003
Figure 3. Inhibition of [125I]VEGF165 binding to the surface of endothelial cells by RAFL antibodies. Log phase or confluent endothelial cell cultures were incubated
with [125I]VEGF165 (25 pM) in the presence of various RAFL antibodies; nonblocking anti-VEGFR2 IgG, 1A8; blocking rabbit polyclonal anti-VEGFR2, TO14;
blocking mouse monoclonal anti-VEGFR1, clone 10.2; or unlabeled VEGF165 (2.5 nM). All antibodies were added at a final concentration of 5 lg/ml. After 4 hours
of incubation at 48C, cells were washed and specific VEGF165 binding was determined as described under Materials and Methods section. The mean percent of
VEGF blocking FSEM is presented. Insert: Relationship between [125I]VEGF165 binding and concentration. A VEGF165 concentration of 25 pM gives about 90%
maximal binding.
Figure 4. Detection of VEGFR2 on vasculature of various tumors by RAFL-1 antibody. NCI-H358 human nonsmall lung carcinoma and L540 Hodgkin’s
disease tumors were grown in SCID mice. Meth A mouse fibrosarcoma and 3LL mouse lung carcinomas were grown in BALB/c and C57BL/6 mice,
respectively. VEGFR2 was detected on frozen tumor sections by incubating them with RAFL-1 antibody (10 lg/ml) followed by goat antirat IgG HRP, as
described under Materials and Methods section. Sections were developed with DAB and counterstained with hematoxylin. Representative images from each
tumor type are shown.
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Localization of Anti-VEGFR2 Antibodies to Flk-1–Positive
Vessels In Vivo
Tumor-bearing mice were intravenously injected with
50 Ag of anti-VEGFR2 or control rat IgG2a antibodies. One
hour later, mice were sacrificed and exsanguinated. The
tumor and organs were removed and snap-frozen for prep-
aration of cryosections. The localized rat IgG was detected
on frozen sections using goat antirat antibody conjugated to
peroxidase (10 Ag/ml). This secondary antibody does not
recognize mouse immunoglobulins present in nude mice.
Inhibition of Tumor Microvasculature in Orthotopic Model of
Breast Cancer
Nude mice (six animals per group) bearing orthotopic
MDA-MB-231 tumors were treated with RAFL-1 antibody
(100 Ag per dose, i.p., every second day). A control group
of mice bearing tumors of similar size (f150 Al) was injected
with saline. The tumor size and general health of the animals
were recorded every 2 to 3 days. Perpendicular tumor
diameters were measured using a Vernier scale caliper.
Tumor volumes were calculated according to the following
equation: volume =D d 2 p/6, whereD is the larger tumor
diameter and d is the smaller diameter. Animal care was in
accordance with institutional guidelines.
After 5 weeks of treatment, mice were anesthesized, and
their blood circulation was perfused with heparinized saline
as described before [25]. The tumor and major organs were
removed and snap-frozen in liquid nitrogen. Cryostat sec-
tions of the tissues were cut and stained for vessels using
pan-endothelial rat antibody antimouse CD31 (PharMingen).
Vessels were counted in 10 fields (two fields from each
quadrant of a cross section and two in the center) at a final
magnification of 100. The mean number of vessels per
square millimeter was calculated.
Statistical Analysis
Results are expressed as meanFSEM, unless otherwise
indicated. Statistical significance was determined by the
Student’s t-test with two-tail analysis. A P value of <.05
was taken as statistically significant.
Results
Generation of Monoclonal Antibodies Against Mouse
VEGFR2
Monoclonal hybridomas were generated by fusing sple-
nocytes from immunized rats with 653CrmA cells or 653
cells. The initial screening of supernatants derived from
653CrmA fusants on immobilized Flk-1 antigen in ELISA
yielded 110 wells having supernatants that were highly
positive (higher than 2 OD), compared with only two wells
in a similarly performed fusion deriving from the 653
cells. The higher fusion efficiency of the CrmA-transfected
myeloma cells has been observed in several fusions and is
possibly due to stable expression of the antiapoptotic
protein, CrmA [24], by myeloma partner cells. From this
extensive primary pool, we selected eight stable clones
(RAFL-1 to RAFL-8) secreting high-affinity antibodies with
diverse functional properties. All the antibodies were rat
IgG2a. All but RAFL-8 had n light chain.
Binding of Anti-VEGFR2 Antibodies to Immobilized Soluble
Domain of Flk-1 in ELISA
RAFL-1 to RAFL-8 antibodies bound strongly and spe-
cifically to sFlk-1 in ELISA. Half-maximal binding was
observed at concentrations that ranged between 10 and 67
pM (Figure 1). RAFL-4 was the antibody having the strongest
binding from this panel with a half-maximal binding of 10 pM.
All antibodies reached saturation at concentrations of 0.2 to
0.4 nM. None of the antibodies reacted with purified mouse
Flt-1 or Flt-4 proteins, which have structural similarity to Flk-1
(data not shown).
Recognition of Mouse VEGFR2 Expressed on Surface of
Cultured EC
The ability of RAFL antibodies to bind to VEGFR2 on
intact fixed or unfixed mouse bEnd.3 endothelial cells was
examined. RAFL-1, RAFL-5, and RAFL-8 stained unfixed
cells but not cells after glutaraldehyde fixation, indicating
preferential recognition of native epitope(s). RAFL-6 stained
fixed cells but not unfixed cells, suggesting that it recognizes
an epitope in denatured VEGFR2. RAFL-2, RAFL-3, and
RAFL-7 bound equally well to native and fixed cells (Table 1).
RAFL-4 did not stain fixed or unfixed cells.
RAFL antibodies bound preferentially to cells in mitosis
(Figure 2, A and B, arrows). Strong binding to cells during
metaphase (Figure 2A) and telophase (Figure 2B) was
observed. Nondividing cells, having distinct nuclear mem-
branes and nucleoli, were more weakly stained (Figure 2,
arrowheads). In contrast, antimouse CD31 antibody uni-
formly stained all endothelial cells with strong intensity
regardless of stage of division (data not shown). This obser-
vation suggests that VEGFR2 on endothelial cells is upregu-
lated during mitotic division.
Blocking of Binding of [125I]VEGF165 to VEGFR2 on Mouse
Endothelial bEnd.3 Cells
The six RAFL antibodies that bound to intact unfixed
cells were tested for their ability to block the binding of
[125I]VEGF165 to VEGFR2 on bEnd.3 cells. We established
in prior experiments that bEnd.3 cells express approximately
equal numbers of Flk-1 and Flt-1 receptors. This is based on
the observation that both antimouse Flk-1 antibody TO14
and antimouse Flt-1 antibody 10.2, when added at a saturat-
ing concentration of 10 Ag/ml, were able to compete out only
f50% of [125I]VEGF165 binding (Figure 3). Thus, antibodies
reactive exclusively to the Flk-1 receptor are expected to
block the binding of VEGF by a maximum of 50%. Non-
competing anti–Flk-1 antibody, 1A8 (10 Ag/ml), reduced the
binding of [125I]VEGF165 by 10% under the same conditions,
indicating that 90% of [125I]VEGF165 was binding specifically
to cell surface receptors.
RAFL-1, RAFL-2, RAFL-3, RAFL-5, RAFL-7, and RAFL-8
inhibited the binding of [125I]VEGF165 to dividing, sparsely
seeded endothelial cells by 33% to 55%, indicating that
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RAFL antibodies are efficient blockers of VEGF interaction
with R2. RAFL-2 was the most efficient antibody in this assay
(Table 1). All competing antibodies had little or no effect on
[125I]VEGF165 binding to confluent monolayers (Figure 3).
This is in accord with the above observation that dividing
endothelial cells have higher surface expression of VEGFR2
than nondividing cells (Figure 2).
Binding to Vascular Endothelial Cells on Frozen
Tumor Sections
The ability of RAFL antibodies to recognize VEGFR2 on
tissue sections was of particular interest because of the
paucity of available reagents having this ability. Two of the
RAFL antibodies (RAFL-1 and RAFL-2) showed strong
recognition of vascular endothelial cells on frozen tumor
sections, ranked as 4+ (Table 1, Figure 4). Four additional
antibodies (RAFL-3, RAFL-5, RAFL-6, and RAFL-7) had
moderate binding, ranked as 2+. RAFL-4 antibody, which
had high affinity for immobilized Flk-1 in ELISA, had no
recognition of the cell surface receptor and did not stain
tumor vessels.
Six different tumors growing in mice were tested for
staining with RAFL-1, RAFL-2, RAFL-3, and RAFL-5. The
tumors were NCI-H358 human NSCLC (Figure 4), L540
human Hodgkin’s disease (Figure 4), Meth A mouse fibro-
sarcoma (Figure 4), 3LL mouse lung tumor (Figure 4), ortho-
topic MDA-MB-431 human breast carcinoma (Figure 5), and
orthotopic L3.6pl human pancreatic carcinoma (Figure 6).
The four antibodies gave similar patterns of staining in each
individual tumor. They stained moderately to strongly
50% to 80% of vessels expressing CD31, a pan-mouse
endothelial marker (Figure 4). This corresponds to 50 to
160 vessels/mm2. Rat IgG2a of irrelevant specificity did not
stain tumor sections. TO14, a rabbit polyclonal antibody to
mouse VEGFR2 [23], showed the same intensity and
pattern distribution of vascular staining as did RAFL anti-
bodies. However, TO14 cross-reacts with cytosolic com-
ponents of the human tumor cells, giving a high
background. In contrast, RAFL antibodies specifically rec-
ognized mouse tumor blood vessels.
Binding to Vascular Endothelial Cells on Sections of Normal
Tissues
A limited panel of normal tissues including heart, lung,
liver, kidney, pancreas, and brain was examined with RAFL
antibodies by direct staining. Vessels in the heart and lungs
(Figure 5), liver, and brain cortex (not shown) were not visibly
stained. In the kidney, RAFL antibodies discretely stained
glomerular endothelium (Figure 5). In the pancreas, most of
the CD31-positive vessels in the islets were positive for
VEGFR2 (Figure 6). Vascular expression of VEGFR2 in
normal kidney glomeruli and pancreas was also confirmed
by a rabbit anti-VEGFR2 antibody, TO14.
Localization of Anti-VEGFR2 Antibodies to Tumor Vessels
in Orthotopic MDA-MB-231 Breast Tumors in Mice
RAFL-1, RAFL-2, RAFL-3, and a control rat IgG2a anti-
body were intravenously injected into nude mice with human
MDA-MB-231 breast tumors growing in their MFPs. One
hour later, the mice were sacrificed and their blood circula-
tion was perfused to remove free antibody. Frozen sections
were prepared from the tumor and normal organs and
examined immunohistochemically to determine the localiza-
tion of the RAFL antibodies or control rat IgG (Figure 5).
About 60% of tumor vessels that were positive for CD31 were
also positive for localized RAFL-1, RAFL-2, and RAFL-3.
Vessels with bound RAFL antibodies were homogeneously
distributedwithin the tumor vasculature. All VEGFR2-positive
vessels detected by direct staining of tumor sections also had
localized RAFL-1, indicating that all VEGFR2-positive ves-
sels were accessible to intravenously administered antibody.
Vessels in normal organs were unstained, with the exception
of the kidney glomeruli (Figure 5) and the pancreas (Figure 6).
Control rat IgG did not localize to tumor or normal vessels in
any of the mice, indicating specificity of detection of anti-
VEGFR2 antibodies.
Inhibition of Tumor Vasculature by RAFL-1 Antibody in
MDA-MB-231 Breast Cancer Model
Groups of six tumor-bearing mice were treated with either
saline or RAFL-1. Mice were sacrificed when the mean tumor
volume of the control and treated groups reached 1250 and
640 mm3, respectively. Treatment with RAFL-1 reduced the
tumor volume by an average of 48%. Tumors from all treated
and control mice were excised and microvessel density and
morphology was assessed as described under Materials and
Methods section.
The mean number of vessels per square millimeter
was 164F7 and 57F5 in control and RAFL-1– treated
groups, respectively. Vessels in control tumors mainly con-
sisted of capillaries that were homogeneously distributed in
all regions except necrotic areas. The vessel phenotype,
number, and distribution of tumors from RAFL-1–treated
mice were strikingly different from those of control tumors
(Figure 7). Microvasculature was almost absent from treated
tumors and residual vessels mainly consisted of mid-sized
mature vessels coated by smooth muscle cells/pericytes.
Necrotic areas occupied 80% to 90% of cross sections,
leaving only a rim of viable cells of approximately 130 Am
in width (Figure 7). No effects were observed on the vascu-
larization of normal MFP epithelium adjacent to treated
tumors. RAFL-1–treated and control mice had similar num-
bers and patterns of vessels in normal MFP epithelium as
well as in other normal organs. These observations indicate
that RAFL-1 treatment specifically inhibits VEGF-dependent
angiogenesis in tumors.
Discussion
The goal of the present study was to generate a panel of
antimouse VEGFR2 monoclonal antibodies to detect mouse
VEGFR2 on frozen sections and to localize to tumor vessels
in vivo. Hybridomas secreting high-affinity antibodies were
generated using a myeloma partner that had been stably
transfected with the antiapoptotic protein, CrmA [24]. The
hybridomas resist apoptosis, enabling a large primary pool of
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Figure 5. Biodistribution of RAFL-1 antibody in mice bearing orthotopic MDA-MB-231 human breast xenografts. Nu/nu mice bearing MDA-MB-231 tumors in their
MFPs were injected intravenously with 50 lg of RAFL-1 antibody. One hour later, their blood circulation was perfused with saline, and tumors and normal organs
were harvested and prepared for cryosectioning. VEGFR2 protein was detected by incubating frozen sections with RAFL-1 antibody and appropriate secondary
antibody (left column). The RAFL-1 antibody that localized to the vasculature after intravenous injection was detected indirectly by incubating sections with
secondary antibody alone (center column). To identify vessels, parallel sections were stained with a pan-endothelial marker, anti-CD31 antibody (right column).
Note that the majority of tumor vessels both express VEGFR2 and display localized RAFL-1 antibody. Kidney glomeruli behave likewise. Neither VEGFR2 protein
nor localized RAFL-1 antibody was detected on vessels of lung or heart.
Figure 6. Expression of VEGFR2 on vessels of normal mouse pancreas and orthotopically implanted human pancreatic tumor, L3.6pl. Human pancreatic tumor,
L3.6pl, was orthotopically grown in nude mice. Frozen sections of normal pancreas from nontumor bearing mice and L3.6pl tumors were stained with RAFL-1
antibody as described above. Arrows indicate stained blood vessels in both types of tissue. Control rat IgG2a did not stain either of the sections.
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positive clones to be selected. Eight hybridomas secreting
high-affinity antibodies to Flk-1 were eventually selected
from this pool (Figure 1). Most of the antibodies competed
with [125I]VEGF165 for the binding to cell surface receptor
(Figure 3). Most RAFL antibodies strongly stained dividing
endothelial cells and had weak reactivity with nondividing
cells present in the same cultures (Figure 2). Similar obser-
vations have been previously reported for mouse antihuman
VEGFR2 antibodies [26].
The most intense detection of VEGFR2 on frozen sec-
tions of various tumors (Figures 4–6) and the most intense
localization to tumor vessels in vivo were obtained with
RAFL-1 and RAFL-2 antibody (Figure 6). VEGFR2 was
observed with this antibody to be a selective tumor endothe-
lial surface marker in ectopic and orthotopic mouse tumors
and human xenografts. VEGFR2 was found in the majority of
the tumor vessels and was homogeneously distributed within
the vascular network. This pattern of expression is partic-
ularly desirable for targeting tumor vasculature as it enables
the attack of both central and peripheral tumor regions.
In prior studies, mRNA for VEGFR2 was detected in the
vascular endothelium in many normal organs [27]. In the
present study, we did not detect VEGFR2 protein on vessels
in normal lung, liver, heart, and brain cortex, although it was
detectable on vessels in kidney glomerulus and pancreatic
islets. The lack of staining of vessels in certain organs may
be due to differences in the sensitivity of mRNA and protein
detection techniques, or to rapid turnover of VEGFR2 protein
on vessels in some organs. The expression of VEGFR2 in
normal kidney glomeruli and pancreatic islets is thought to be
required for maintenance of high vascular permeability
[28,29].
The expression of VEGFR2 in kidney glomerulus and
pancreatic islets raises the question of whether agents
directed against VEGFR2 have sufficient specificity for
tumor vessels to be useful for vascular targeting therapy.
Several lines of evidence suggest that cytotoxic or pro-
thrombotic effects of agents targeted to VEGFR2 might be
tolerated by normal vessels. First, the level of VEGFR2
expression is higher on dividing endothelial cells, which are
abundant in malignant tumors. Second, intracellular traf-
ficking of an internalized anti–VEGFR2–toxin conjugate
may differ between dividing and quiescent endothelia in
that only in dividing cells can the conjugates reach a
compartment from which the toxin moiety can escape into
cytosol. This mechanism has been previously proposed to
explain why dividing endothelial cells are 60-fold more
sensitive to VEGF gelonin toxin than are confluent, quies-
cent endothelial cells [30]. Third, vascular targeting agents
containing tissue factor as an effector moiety require coinci-
dent expression of a target molecule and phosphatidylserine
for the induction of the coagulation cascade [31–33]. Endo-
thelial cells in tumors expose phosphatidylserine on their
luminal surface, whereas endothelial cells in resting normal
organs do not [34]. We have previously demonstrated that
the absence of externalized phosphatidylserine from the
surface of VCAM-1–positive normal vessels prevented the
action of anti–VCAM-1–tissue factor conjugate and averted
toxicity [34]. Renal or pancreatic toxicities have not been
reported for other VEGFR2 targeting or blocking reagents
either in the mouse or clinical studies despite expression of
VEGFR2 on vessels in these organs [35–37].
We demonstrate here that unconjugated RAFL anti-
bodies directed against native Flk-1 receptor efficiently
Figure 7. RAFL-1 antibody reduces microvascular density in MDA-MB-231 human breast tumors growing in the MFP of mice. Tumors from RAFL-1– treated (A) or
rat IgG control antibody-treated (B) mice were removed, frozen sections were cut, and microvessels were detected by anti-CD31 antibody. Microvascular densities
were determined on six individual slides per experimental group and the results were averaged. The mean number of vessels per square millimeter was 164F7 and
57F5 in control and RAFL-1– treated groups, respectively. Representative images of tumors derived from control and RAFL-1– treated mice are shown. Note the
absence of microvasculature and the extent of necrosis in tumor from RAFL-1– treated mice compared to a fully viable and highly vascularized tumor from the
control group.
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blocked VEGF binding to dividing endothelial cells (Figure 3)
and inhibited the formation of tumor neovasculature in vivo
(Figure 7). Treatment with anti-VEGFR2 antibody had no
effect on morphology or number of vessels in normal
tissues, indicating specific inhibition of VEGF-driven angio-
genesis. These findings are in accord with prior observa-
tions [21,38]. It is possible that inhibition of binding of VEGF
to VEGFR2 denies dividing remodeling endothelial cells
VEGF-mediated survival signals, leading to their demise,
whereas quiescent endothelium is not dependent on VEGF
signals for survival.
In summary, our findings with RAFL antibodies confirm
that VEGFR2 is strongly and consistently expressed on
blood vessels in a variety of solid tumors, and suggest that
anti-VEGFR2 antibodies could be used to deliver toxins,
tissue factor, or radionuclides to tumor vasculature.
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